Autoimmune diseases afflict a significant portion of the US population, with the most common age of onset being during young adulthood leading to increased morbidity, early mortality and accrual of damage with associated disability, oftentimes early in life. Many of the systemic autoimmune diseases are characterized by a waxing and waning, or relapsing/remitting, course. These periods of increased disease activity, oftentimes with permanent organ-damage, are interspersed on a background of clinical suppression or quiescence. Although shared across many of the systemic autoimmune diseases, the mechanisms or predictors of disease flares are very poorly understood or not understood at all. This application will focus on understanding mechanisms of disease flare in SLE and then collaborating with other ACE centers, to expand these studies and evaluate which of these mechanisms are common across a number of autoimmune diseases or are disease specific. Over the past funding cycle, our Oklahoma ACE has established and expanded a number of patient collections which have provided insights or samples which will be relevant to understanding mechanisms of SLE disease flare. In preliminary studies of European American SLE patients who exhibited a disease flare within 6 or 12 weeks of baseline assessment compared to patients who did not flare, alterations in 27 soluble mediators {p<0.01) were found at baseline compared to non-flare patients, with significantly higher levels of pro-inflammatory mediators several weeks before clinical flare. Regulatory cytokines were increased at baseline in non-flare SLE patients. Nearly all of these abnormalities were also found in the SLE patients during their flare year compared to samples from these individuals in a non-flare year. Based upon these and other presented preliminary data, we hypothesize that critical alterations in cellular activation, TNF receptor shedding, innate and adaptive mediators of inflammation, and regulatory immune cell pathways are present immediately preceding SLE disease flare. We will test these hypotheses through the following specific aims: 1) determine alterations in innate and adaptive immune cell populations, functional responses and serologic biomarkers in SLE patients immediately before flare compared to matched SLE patients who do not flare, as well as in longitudinal samples;2) evaluate parent cellular populations, levels, locations and functional consequences of shed TNF and other immune receptors in SLE patients temporally preceding a clinical disease flare;and 3) assess the frequency and function of regulatory B and T cells temporally preceding SLE disease flare.

Public Health Relevance

Autoimmune diseases affect 5-7% of the population and often have has periods of disease flares interspersed with disease suppression. This project aims to identify mechanisms responsible for disease flare and predictors of disease flare that are currently unknown or poorly understood to help aid earlier diagnosis, design appropriate clinical trials, develop new directed therapeutic agents and help guide therapy selection to improve the lives of patients with autoimmune diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
2U19AI082714-06
Application #
8732896
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
6
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Oklahoma Medical Research Foundation
Department
Type
DUNS #
City
Oklahoma City
State
OK
Country
United States
Zip Code
73104
Munroe, Melissa E; Vista, Evan S; Merrill, Joan T et al. (2017) Pathways of impending disease flare in African-American systemic lupus erythematosus patients. J Autoimmun 78:70-78
Arriens, Cristina; Wren, Jonathan D; Munroe, Melissa E et al. (2017) Systemic lupus erythematosus biomarkers: the challenging quest. Rheumatology (Oxford) 56:i32-i45
Aberle, Teresa; Bourn, Rebecka L; Chen, Hua et al. (2017) Use of SLICC criteria in a large, diverse lupus registry enables SLE classification of a subset of ACR-designated subjects with incomplete lupus. Lupus Sci Med 4:e000176
Langefeld, Carl D; Ainsworth, Hannah C; Cunninghame Graham, Deborah S et al. (2017) Transancestral mapping and genetic load in systemic lupus erythematosus. Nat Commun 8:16021
Munroe, Melissa E; Young, Kendra A; Kamen, Diane L et al. (2017) Discerning Risk of Disease Transition in Relatives of Systemic Lupus Erythematosus Patients Utilizing Soluble Mediators and Clinical Features. Arthritis Rheumatol 69:630-642
Glauzy, Salomé; Boccitto, Marco; Bannock, Jason M et al. (2017) Accumulation of Antigen-Driven Lymphoproliferations in Complement Receptor 2/CD21-/low B Cells From Patients With Sjögren's Syndrome. Arthritis Rheumatol :
Jog, Neelakshi R; James, Judith A (2017) Biomarkers in connective tissue diseases. J Allergy Clin Immunol 140:1473-1483
Merrill, Joan T; Immermann, Fred; Whitley, Maryann et al. (2017) The Biomarkers of Lupus Disease Study: A Bold Approach May Mitigate Interference of Background Immunosuppressants in Clinical Trials. Arthritis Rheumatol 69:1257-1266
Young, Kendra A; Munroe, Melissa E; Guthridge, Joel M et al. (2017) Combined role of vitamin D status and CYP24A1 in the transition to systemic lupus erythematosus. Ann Rheum Dis 76:153-158
Sandhya, Pulukool; Kurien, Biji Theyilamannil; Danda, Debashish et al. (2017) Update on Pathogenesis of Sjogren's Syndrome. Curr Rheumatol Rev 13:5-22

Showing the most recent 10 out of 116 publications